Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 12/20 | 0.61 |
| ▸ | FLT1 | P17948 | 12/20 | 0.61 |
| ▸ | EGFR | P00533 | 11/20 | 0.61 |
| ▸ | FLT4 | P35916 | 9/20 | 0.61 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.46 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6519244 | 0.82 | KDR (0.59) | KDRFGFR1FLT1EGFRFLT4 | |
| SCHEMBL5411253 | 0.82 | KDR (0.61) | KDRFGFR1FLT1EGFRFLT4 | |
| Hydrochloric Acid SCHEMBL6462110 | 0.81 | KDR (0.62) | KDRFGFR1FLT1EGFRFLT4 | |
| Hydrochloric Acid SCHEMBL6517812 | 0.80 | KDR (0.54) | KDRFGFR1FLT1EGFRFLT4 | |
| SCHEMBL1889714 | 0.79 | FGFR1 (0.58) | KDRFGFR1FLT1EGFRFLT4 | |
| SCHEMBL1896917 | 0.79 | FGFR1 (0.58) | KDRFGFR1FLT1EGFRFLT4 | |
| SCHEMBL1885305 | 0.79 | FGFR1 (0.58) | KDRFGFR1FLT1EGFRFLT4 | |
| SCHEMBL6487092 | 0.79 | KDR (0.51) | KDRFGFR1FLT1EGFRFLT4 | |
| SCHEMBL6477341 | 0.79 | KDR (0.61) | KDRFGFR1FLT1EGFRFLT4 | |
| SCHEMBL7738587 | 0.78 | KDR (0.60) | KDRFGFR1FLT1EGFRFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020173646-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | ZENECA LIMITED | 2002-11-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173646-A1 | Quinazoline derivatives and pharmaceutical compositions containing them | CNKSR1, FLT1, VEGFA | KDR 4/4885FGFR1 195/4885FLT1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.